Trial Profile

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 022 (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

09 Dec 2019 Results (n=20) presented in the Gracell Biotechnology Media Release.
15 Nov 2019 Results published in the Gracell Biotechnology Media Release.
06 Nov 2019 Safety and efficacy results (n=17) released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com